|
1) Ritz P, Dumas JF, Ducluzeau PH, et al. Hormonal regulation of mitochondrial energy production. Curr Opin Clin Nutr Metab Care. 2005; 8: 415-8
|
|
|
|
2) Mitsuishi M, Miyashita K, Itoh H. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun. 2008; 367: 840-5
|
|
|
|
|
|
3) Miyashita K, Itoh H, Tsujimoto H, et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009; 58: 2880-92
|
|
|
|
|
|
4) Mitsuishi M, Miyashita K, Muraki A, et al. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes. 2009; 58: 710-7
|
|
|
|
|
|
5) Wang TJ, Larson MG, Keyes MJ, et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007; 115: 1345-53
|
|
|
|
|
|
6) Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109: 594-600
|
|
|
|
|
|
7) Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005; 23: 463-73
|
|
|
|
|
|
8) Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369: 201-7
|
|
|
|
|
|
9) Hoppeler H, Fluck M. Plasticity of skeletal muscle mitochondria: structure and function. Med Sci Sports Exerc. 2003; 35: 95-104
|
|
|
|
|
|
10) Kelley DE, He J, Menshikova EV, et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002; 51: 2944-50
|
|
|
|
|
|
11) Ritov VB, Menshikova EV, He J, et al. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005; 54: 8-14
|
|
|
|
|
|
12) Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004; 350: 664-71
|
|
|
|
|
|
13) Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003; 100: 8466-71
|
|
|
|
|
|
14) Sparks LM, Xie H, Koza RA, et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes. 2005; 54: 1926-33
|
|
|
|
|
|
15) Civitarese AE, Carling S, Heilbronn LK, et al. CALERIE Pennington Team. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007; 4: e76
|
|
|
|
|
|
16) Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000; 49: 677-83
|
|
|
|
|
|
17) Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol. 2009; 9: 780-6
|
|
|
|
|
|
18) Russell SJ, Kahn CR. Endocrine regulation of ageing. Nat Rev Mol Cell Biol. 2007; 8: 681-91
|
|
|
|
|
|
19) Scheller K, Sekeris CE. The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation. Exp Physiol. 2003; 88: 129-40
|
|
|
|
|
|
20) Roussel D, Dumas JF, Augeraud A, et al. Dexamethasone treatment specifically increases the basal proton conductance of rat liver mitochondria. FEBS Lett. 2003; 541: 75-9
|
|
|
|
|
|
21) Connaughton S, Chowdhury F, Attia RR, et al. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol. 2010; 315: 159-67
|
|
|
|
|
|
22) Cioffi F, Lanni A, Goglia F. Thyroid hormones, mitochondrial bioenergetics and lipid handling. Curr Opin Endocrinol Diabetes Obes. 2010; 17: 402-7
|
|
|
|
|
|
23) Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov. 2009; 8: 308-20
|
|
|
|
|
|
24) Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362: 906-16
|
|
|
|
|
|
25) Moro C, Crampes F, Sengenes C, et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J. 2004; 18: 908-10
|
|
|
|
|
|
26) Kalra PR, Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol. 2002; 85: 125-32
|
|
|
|
|
|
27) Kim JW, Tchernys hyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3: 177-85
|
|
|
|
|
|
28) Aragonés J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008; 40: 170-80
|
|
|
|
|
|
29) Fukuda R, Zhang H, Kim JW, et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007; 129: 111-22
|
|
|
|
|
|
30) Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009; 24: 97-106
|
|
|
|
|
|
31) Solinas G, Summermatter S, Mainieri D, et al. The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. FEBS Lett. 2004 19; 577: 539-44
|
|
|
|
|
|
32) Orci L, Cook WS, Ravazzola M, et al. Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci U S A. 2004; 101: 2058-63
|
|
|
|
|